Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions

References

• BinazonODubois-GaucheANanauRMNeumanMGEfficacy and safety of platelet inhibitorsJ Pharm Pharm Sci201316113923683603
   PubMed Web of Science ®Google Scholar
• GouyaGArrichJWolztMAntiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysisStroke201445249250324368560
   PubMed Web of Science ®Google Scholar
• HankeyGJReplacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?Curr Opin Neurol2010231657219949330
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPHiattBLO’ConnorCMClopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivityCirculation20031072908291312796140
   PubMed Web of Science ®Google Scholar
• FareedJJeskeWThethiIMetabolic differences of current thienopyridine antiplatelet agentsExpert Opin Drug Metab Toxicol20139330731723289968
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug AdministrationFDA Drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug Available form: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm (March 12, 2010)Accessed January 31, 2015
   Google Scholar
• MegaJLCloseSLWiviottSDCytochrome p-450 polymorphisms and response to clopidogrelN Engl J Med2009360435436219106084
   PubMed Web of Science ®Google Scholar
• MaTKWLamYYTanVPYanBPVariability in response to clopidogrel: how important are pharmacogenetics and drug interactions?Br J Clin Pharmacol201172469770621352268
   PubMed Web of Science ®Google Scholar
• FusterVSweenyJMClopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzleJAMA20103041839184020978263
   PubMed Web of Science ®Google Scholar
• ShuldinerARO’ConnellJRBlidenKPAssociation of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302884985719706858
   PubMed Web of Science ®Google Scholar
• ScottSASangkuhlKSteinCMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 updateClin Pharmacol Ther201394331732323698643
   PubMed Web of Science ®Google Scholar
• GoutelleSBourguignonLBleyzacNBerryJClavel-GrabitFTodMIn vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substratesAAPS J201315241542623319287
   PubMed Web of Science ®Google Scholar
• CastellanCCharpiatBGueyffierFKassaïBNonyPGenophar II working groupDDI-predictor Available from: http://www.ddi-predictor.org/Accessed January 31, 2015
   Google Scholar
• BertilssonLGeographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19Clin Pharmacokinet19952931922098521680
   PubMed Web of Science ®Google Scholar
• DestaZZhaoXShinJGFlockhartDAClinical significance of the cytochrome P450 2C19 genetic polymorphismClin Pharmacokinet2002411291395812222994
   PubMed Web of Science ®Google Scholar
• SimonTBhattDLBergougnanLGenetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjectsClin Pharmacol Ther201190228729521716274
   PubMed Web of Science ®Google Scholar
• GladdingPWebsterMZengIThe antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trialJACC Cardiovasc Interv20081661261919463374
   PubMed Web of Science ®Google Scholar
• GladdingPWhiteHVossJPharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation studyJACC Cardiovasc Interv20092111095110119926050
   PubMed Web of Science ®Google Scholar
• BarkerCMMurraySSTeirsteinPSKandzariDETopolEJPriceMJPilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivityJACC Cardiovasc Interv20103101001100720965456
   PubMed Web of Science ®Google Scholar
• BonelloLArmeroSAit MokhtarOClopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphismJ Am Coll Cardiol201056201630163620708365
   PubMed Web of Science ®Google Scholar
• AlexopoulosDDimitropoulosGDavlourosPPrasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotypingJACC Cardiovasc Interv20114440341021511219
   PubMed Web of Science ®Google Scholar
• ColletJPHulotJSAnzahaGCLOVIS-2 InvestigatorsHigh doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)JACC Cardiovasc Interv20114439240221511218
   PubMed Web of Science ®Google Scholar
• HamilosMMullerONtalianisARelationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrelJ Thromb Thrombolysis2011321647121290254
   PubMed Web of Science ®Google Scholar
• MegaJLHochholzerWFrelingerAL3rdDosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular diseaseJAMA2011306202221222822088980
   PubMed Web of Science ®Google Scholar
• PriceMJBergerPBTeirsteinPSGRAVITAS InvestigatorsStandard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trialJAMA2011305111097110521406646
   PubMed Web of Science ®Google Scholar
• BonelloLPansieriMManciniJHigh on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromesJ Am Coll Cardiol201158546747321777742
   PubMed Web of Science ®Google Scholar
• BarthélémyOSilvainJBriegerDBleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial centerCatheter Cardiovasc Interv201279110411222162411
   PubMed Web of Science ®Google Scholar
• CaldeiraDFernandesRCostaJBranded versus generic clopidogrel in cardiovascular diseases: a systematic reviewJ Cardiovasc Pharmacol201361427728223188124
   PubMed Web of Science ®Google Scholar
• WallentinLVarenhorstCJamesSPrasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseEur Heart J200829213018055486
   PubMed Web of Science ®Google Scholar